MIT develops a new vaccine offering protection against SARS-CoV-2 variants and related sarbecoviruses, addressing future pandemic threats.
A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
President Donald Trump announced a $500billion investment for private companies to develop artificial intelligence tools to ...
Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.